Drugmakers oppose expert “hot tubbing” in UK excessive pricing trial
Two drugmakers seeking to overturn nearly £70 million in excessive pricing penalties have urged the UK's Competition Appeal Tribunal not to compel concurrent expert evidence.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.